CRO support for ncats regulatory affairs and related services

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N95022D00014
Awardee
Awarding agency
Task orders
3 $366,134 obligated

Award facts

Opportunity
Combined order value
  • $366,134 Current, with exercised options
  • $1,951,651 Potential, with all options
Last date to order 88% complete
IDV ceiling 2% used
$19,364,880.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute on Drug Abuse awarded a multiple-award indefinite-delivery contract to MPF Federal, LLC, a total small business set-aside with a ceiling of $19,364,880 on June 10, 2022. The IDIQ is designated for Economically Disadvantaged Women-Owned Small Business, Women-Owned Small Business, and HUBZone support for CRO services and regulatory affairs related to the National Center for Advancing Translational Sciences (NCATS) mission. The contract runs through June 9, 2027.

Place of performance spans NCATS locations, with delivery orders executed from Montgomery Village, Maryland and Philadelphia, Pennsylvania. The IDIQ solicitation, posted December 14, 2020, sought regulatory support and contract research organization services to advance translational science initiatives and support the development of therapeutic candidates through regulatory pathways.

Three delivery orders have been issued under this IDIQ. In September 2022, NCATS issued a labor-hour delivery order valued at $1,189,645.80 for regulatory support on lead gene therapy candidates addressing propionic acidemia and methylmalonic acidemia type B, with performance through September 21, 2025. In September 2023, NCATS issued a $654,181 labor-hour delivery order for regulatory support on BITOX, a detoxified botulism neurotoxin therapeutic for chronic neuropathic pain, extending through September 21, 2026. Most recently, on August 24, 2026, NCATS issued a firm fixed-price delivery order for $107,824.17 supporting regulatory work on an endosome-targeted therapeutic agent for chronic pain treatment, with completion scheduled for August 23, 2029.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00004 · EO14398 CRO support for ncats regulatory affairs and related services $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Supplemental Agreement for work within scope P00001 $0
Original award $1,000

Quick answers

Who was awarded contract 75N95022D00014?

75N95022D00014 was awarded to MPF Federal, LLC by National Institute on Drug Abuse (National Institutes of Health) on June 10, 2022.

How much is contract 75N95022D00014 worth?

Orders under 75N95022D00014 have obligated $366,134. Their combined potential value, with all options, is $1,951,651. 75N95022D00014's own ceiling is $19,364,880.

How many orders have been placed under contract 75N95022D00014?

3 orders have been placed under 75N95022D00014, the latest on August 24, 2026.

Who can order from contract 75N95022D00014?

75N95022D00014 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N95022D00014 competed?

The extent of competition for 75N95022D00014 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV